- Home
- CRNX vs FE Comparison
CRNX vs FE Comparison
Compare CRNX & FE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRNX | FE |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 28.1B |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CRNX | FE |
|---|---|---|
| Price | $84.69 | $47.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $76.75 | $51.46 |
| AVG Volume (30 Days) | 2.5M | ★ 3.4M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.80% |
| EPS Growth | N/A | ★ 3.53 |
| EPS | N/A | ★ 0.70 |
| Revenue | $1,039,000.00 | ★ $15,090,000,000.00 |
| Revenue This Year | $720.10 | $4.34 |
| Revenue Next Year | $184.67 | $3.98 |
| P/E Ratio | ★ N/A | $67.51 |
| Revenue Growth | N/A | ★ 12.01 |
| 52 Week Low | $29.63 | $42.87 |
| 52 Week High | $84.80 | $52.34 |
Technical Indicators
Market Signals| Indicator | CRNX | FE |
|---|---|---|
| Relative Strength Index (RSI) | 89.80 | 45.96 |
| Support Level | $83.47 | $46.40 |
| Resistance Level | N/A | $47.71 |
| Average True Range (ATR) | 0.22 | 0.86 |
| MACD | -1.24 | -0.06 |
| Stochastic Oscillator | 92.34 | 37.26 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
About FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with operations across five mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.